RecruitingNot ApplicableNCT02370199

Peripheral Blood Flow Responses to Electromagnetic Energy

Sponsor

University of Alabama at Birmingham

Enrollment

40 participants

Start Date

Nov 1, 2014

Study Type

INTERVENTIONAL

Conditions

Exposure to Man-made Visible Light

Summary

This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.

Eligibility

Min Age: 18 YearsMax Age: 59 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called 670 nm light and a drug called octafluropropane for people with exposure to man-made visible light. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 59 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE670 nm light

670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.

DRUGoctafluropropane

Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.

Locations(1)

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02370199